Ionis Pharma upgraded by Bernstein with a new price target
$IONS
Biotechnology: Pharmaceutical Preparations
Health Care
Bernstein upgraded Ionis Pharma from Underperform to Mkt Perform and set a new price target of $44.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $70.00 | Market Perform → Outperform | BMO Capital Markets |
| 7/31/2025 | $62.00 | Equal-Weight → Overweight | Morgan Stanley |
| 7/1/2025 | $57.00 | Equal Weight → Overweight | Barclays |
| 4/7/2025 | $45.00 | Buy | H.C. Wainwright |
| 3/31/2025 | $39.00 | Neutral | Redburn Atlantic |
| 8/2/2024 | $67.00 → $60.00 | Outperform → Market Perform | BMO Capital Markets |
| 7/24/2024 | $53.00 → $62.00 | Market Perform → Outperform | Leerink Partners |
| 7/16/2024 | $29.00 → $75.00 | Buy | Jefferies |
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
- Pivotal Phase 3 REVEAL study enrollment on track to complete in 2026 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome (AS), a rare neurological disease that often presents in infancy and is characterized by profound intellectual disability, impaired communication, motor impairment and debilitating seizures. "With no approved disease-modifying treatments available for people living with Angelman syndrome, receiving this Breakthrough Therapy designation for ION582 underscores both the severity of this disease and the significant unmet
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that it will host Ionis Innovation Day on Tuesday, October 7, 2025, in New York. The agenda will feature presentations from members of the Ionis leadership team as well as a key thought leader in the treatment of severe hypertriglyceridemia, familial chylomicronemia syndrome and lipid disorders, Robert D. Fishberg, M.D., cardiologist with Atlantic Medical Group in Springfield, NJ, and assistant clinical professor of medicine at the Sidney Kimmel Medical College, Thomas Jefferson University. The presentations will be webcast live from 8:30 a.m. to 12:30 p.m. Eastern time. Please click here to register for the event. A webcast re
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time. About Ionis Pharm
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)
BMO Capital Markets upgraded Ionis Pharma from Market Perform to Outperform and set a new price target of $70.00
Morgan Stanley upgraded Ionis Pharma from Equal-Weight to Overweight and set a new price target of $62.00
Barclays upgraded Ionis Pharma from Equal Weight to Overweight and set a new price target of $57.00
144 - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
144 - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B
SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)
- TRYNGOLZATM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approval in hereditary angioedema (HAE) anticipated next month; Ionis' second independent launch - - Phase 3 data from the pivotal CORE and CORE2 studies in severe hypertriglyceridemia (sHTG) expected in September 2025 - - Increasing 2025 financial guidance based on strong performance and improved outlook - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results and provided key updates for the second quarter ended June 30, 2025. "During the second quarter, we continued to build momentum across our business," said Brett P. Monia, Ph.D., chief execu
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of
- Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m